Isoniazid preventive therapy for tuberculosis in South Africa: An assessment of the local evidence base

South African Medical Journal

Volumn 104, Issue 3, 2014, Pages 174-177

  Wood, Robin ^a   Bekker, Linda Gail ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV; Isoniazid; Prevention; Tuberculosis

Indexed keywords

ISONIAZID;

CD4 LYMPHOCYTE COUNT; DISEASE COURSE; FOLLOW UP; HEALTH CARE; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; META ANALYSIS (TOPIC); MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NUTRITIONAL STATUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM CULTURE; TUBERCULIN TEST; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

HUMANS; ISONIAZID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOUTH AFRICA; TUBERCULOSIS;

EID: 84894730184     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.7968     Document Type: Review

References (36)

1. WHO Department of HIV/AIDS, Stop TB Department. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings. Geneva: WHO, 2010. http://www.who.int/hiv/pub/tb/9789241500708/en/ (accessed 10 February 2014).
2. Joint United Nations Programme on HIV/AIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva: UNAIDS, 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf (accessed 10 February 2014).
3. Wood R, Lawn SD, Caldwell J, et al. Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS One 2011;6(10):e25098. [http://dx.doi.org/10.1371/journal.pone.0025098]
4. Wood R, Lawn SD, Johnstone-Robertson S, Bekker L-G. Tuberculosis control has failed in South Africa-time to reappraise strategy. S Afr Med J 2011;101(2):111-114.
5. National Department of Health. Guidelines for Tuberculosis Preventive Therapy Among HIV Infected Individuals in South Africa. Pretoria: NDoH, 2010. http://www.sasohn.co.za/images/TB%20prophylaxis%20in%20South%20Africa%20final%20%2031%2003%2010.pdf (accessed 10 February 2014).
6. National Department of Health. South African Antiretroviral Treatment Guidelines 2013. Pretoria: NDoH, 2013. http://www.sahivsoc.org/upload/documents/2013%20ART%20Guidelines-Short%20Combined%20FINAL%20draft%20guidelines%2014%20March%202013.pdf (accessed 10 February 2014).
7. Fielding KL, Grant AD, Hayes RJ, Chaisson RE, Corbett EL, Churchyard GJ. Thibela TB: Design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. Contemp Clin Trials 2011;32(3):382-392. [http://dx.doi.org/10.1016/j.cct.2010.12.008]
8. Zorini AO. Sul nuovo metodo di chemioprofilassi antitubercolare mediante isoniazide. Rivista Tuberc Malattie Appar Resp 1956;4:403-437.
9. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1969;17:28-106.
10. Bass JB Jr, Farer LS, Hopewell PC, et al; American Thoracic Society, Centers for Disease Control, American Academy of Pediatrics. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-1374. [http://dx.doi.org/10.1164/ajrccm.149.5.8173779]
11. Smieja MJ, Marchelli CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000;(2):CD001363. [http://dx.doi.org/10.1002/14651858.CD001363]
12. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010;(1):CD000171. [http://dx.doi.org/10.1002/14651858.CD000171.pub3]
13. Mohammed A, Myer L, Ehrlich R, Wood R, Cilliers F, Maartens G. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Int J Tuberc Lung Dis 2007;11(10):1114-1120.
14. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: Randomised controlled trial. BMJ 2007;334(7585):136. [http://dx.doi.org/10.1136/bmj.39000.486400.55]
15. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011;365(1):21-31. [http://dx.doi.org/10.1056/NEJMoa1011214]
16. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: A randomised double-blind placebo-controlled trial. Lancet (in press).
17. Churchyard GJ, Fielding KL, Lewis JJ, et al. Community-wide Isoniazid Preventive Therapy Does Not Improve Tuberculosis Control Among Gold Miners in South Africa: The Thibela TB study; Abstracts presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, USA. 5-8 March 2012. Abstract #150aLB.
18. Fielding K. Individual-level Effect of Isoniazid Preventive Therapy on Risk of TB: The Thibela TB Study. Abstract presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, USA. 5-8 March 2012. Abstract #150bLB, 2012.
19. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A; Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54(RR-15):49-55.
20. Lin PL, Ford CB, Coleman MT, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 2014;20:75-79. [http://dx.doi.org/10.1038/nm.3412]
21. Menzies R. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159(1):15-21. [http://dx.doi.org/10.1164/ajrccm.159.1.9801120]
22. Horsburgh CR. Priorities for treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350(20):2060-2067. [http://dx.doi.org/10.1056/NEJMsa031667]
23. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012;54(6):784-791. [http://dx.doi.org/10.1093/cid/cir951]
24. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1 infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000;23(1):75-80. [http://dx.doi.org/10.1097/00042560-200001010-00010]
25. Kerkoff AD, Kranzer K, Samandari T, et al. Systematic review of TST responses in people living with HIV in under-resourced settings: Implications for isoniazid preventive therapy. PLoS One 2012;7(11):e49928. [http://dx.doi.org/10.1371/journal.pone.0049928]
26. Lawn SD, Myer L, Bekker L-G, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 2006;6:59. [http://dx.doi.org/10.1186/1471-2334-6-59]
27. Lawn SD, Bekker L-G, Wood R. How effectively does antiretroviral treatment of HIV restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005;19(11):1113-1124.
28. Nardell E, Churchyard G. What is thwarting tuberculosis prevention in high-burden settings? N Engl J Med 2011;365(1):79-81. [http://dx.doi.org/10.1056/NEJMe1105555]
29. Mills HL, Cohen T, Colijn C. Community-wide isoniazid therapy drives drug-resistant tuberculosis: A model-based analysis. Sci Transl Med 2013;5(180):180ra49. [http://dx.doi.org/10.1126/scitranslmed.3005260]
30. Madhi SA, Kim S, Mitchell C. Isoniazid prophylaxis against tuberculosis in children. N Engl J Med 2011;365(1):1543-1544. [http://dx.doi.org/10.1056/NEJMoa1011214]
31. Churchyard GJ, Fielding KL, Lewis JJ, Chihota VN, Hanifa Y, Grant AD. Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: Yield and proportion missed at screening. AIDS 2010;24(Suppl 5):S19-S27. [http://dx.doi.org/10.1097/01.aids.0000391018.72542.46]
32. Van Halsema CL, Fielding KL, Chihota VN, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010;24(7):1051-1055. [http://dx.doi.org/10.1097/QAD.0b013e32833849df]
33. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis in HIV-infected adults in South Africa: A prospective cohort. AIDS 2009;23:631-636. [http://dx.doi.org/10.1097/QAD.0b013e328327964f]
34. Wood R, Lawn SD, Bekker L-G. Are the effects of isoniazid preventive therapy and HAART additive in preventing of HIV-associated tuberculosis? AIDS 2009:23(11):1444-1446. [http://dx.doi.org/10.1097/QAD.0b013e32832d53e7]
35. Charalambous S, Grant AD, Innes C, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010;24 (Suppl 5):S5-S13. [http://dx.doi.org/10.1097/01.aids.0000391010.02774.6f]
36. Wood R, Liang H, Wu H, et al. Changing prevalence of TB infection with increasing age in high TB burden townships in South Africa. Int J Tuberc Lung Dis 2010;14(4):406-412.